Inovio says Covid-19 vaccine produces antibodies in mice, guinea pigs
Experts predict a safe and effective vaccine could take 12 to 18 months to develop
Small bottles labelled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. PHOTO: REUTERS/FILE
US immunotherapy company Inovio Pharmaceuticals Inc on Wednesday said its experimental vaccine to prevent coronavirus infection was shown to produce protective antibodies and immune system responses in mice and guinea pigs.
The company’s shares, which have more than quadrupled this year, surged 17.7% to $17.13 in trading before the bell.
“We saw antibody responses that do many of the things we would want to see in an eventual vaccine,” said Dr David Weiner, director of the vaccine and immunotherapy centre at the Wistar Institute, which has collaborated with Inovio. “We are able to target things that would prevent the virus from having a safe harbour in the body.”
There are currently no approved treatments or vaccines for Covid-19, the disease caused by the new coronavirus. Experts predict a safe and effective vaccine could take 12 to 18 months to develop.
Scientists posit llama antibodies could be significant in beating Covid-19
Inovio, which began human testing of its vaccine in April, said preliminary results from that trial are expected in June. The 40 healthy participants in the Phase 1 trial are given two shots, four weeks apart, of the vaccine, called INO-4800, and then followed for two weeks.
“We are already seeing safety data and it has been benign,” Dr Katherine Broderick, head of research and development at Inovio, told Reuters. “Some people have slight redness of the arm.”
Once the preliminary data are in, she said Inovio expects to approach the U.S. Food and Drug Administration for authorisation to move into a Phase 2/3 trial, which could happen in July or August.
Inovio said the latest animal study results, published in the journal Nature Communications, validate its DNA medicines platform and build on previous positive clinical trial data for its experimental vaccine against a different, but related, coronavirus that causes Middle East Respiratory Syndrome.
That vaccine and INO-4800 are made using newer technology that focuses on specific genes on the outer “spike” portion of the virus.
Inovio said the newly published data demonstrate virus-neutralising activity using three separate testing procedures.
'Promising' virus-fighting antibody found: study
Study authors also said they detected the antibodies in the lungs of the vaccinated animals.
Inovio next plans to test the vaccine in larger animals including rabbits and monkeys, and to undertake “challenge” studies in mice, ferrets and monkeys, Broderick said. Challenge studies involve intentionally giving the virus to an animal and then seeing if the vaccine prevents infection.
The company’s shares, which have more than quadrupled this year, surged 17.7% to $17.13 in trading before the bell.
“We saw antibody responses that do many of the things we would want to see in an eventual vaccine,” said Dr David Weiner, director of the vaccine and immunotherapy centre at the Wistar Institute, which has collaborated with Inovio. “We are able to target things that would prevent the virus from having a safe harbour in the body.”
There are currently no approved treatments or vaccines for Covid-19, the disease caused by the new coronavirus. Experts predict a safe and effective vaccine could take 12 to 18 months to develop.
Scientists posit llama antibodies could be significant in beating Covid-19
Inovio, which began human testing of its vaccine in April, said preliminary results from that trial are expected in June. The 40 healthy participants in the Phase 1 trial are given two shots, four weeks apart, of the vaccine, called INO-4800, and then followed for two weeks.
“We are already seeing safety data and it has been benign,” Dr Katherine Broderick, head of research and development at Inovio, told Reuters. “Some people have slight redness of the arm.”
Once the preliminary data are in, she said Inovio expects to approach the U.S. Food and Drug Administration for authorisation to move into a Phase 2/3 trial, which could happen in July or August.
Inovio said the latest animal study results, published in the journal Nature Communications, validate its DNA medicines platform and build on previous positive clinical trial data for its experimental vaccine against a different, but related, coronavirus that causes Middle East Respiratory Syndrome.
That vaccine and INO-4800 are made using newer technology that focuses on specific genes on the outer “spike” portion of the virus.
Inovio said the newly published data demonstrate virus-neutralising activity using three separate testing procedures.
'Promising' virus-fighting antibody found: study
Study authors also said they detected the antibodies in the lungs of the vaccinated animals.
Inovio next plans to test the vaccine in larger animals including rabbits and monkeys, and to undertake “challenge” studies in mice, ferrets and monkeys, Broderick said. Challenge studies involve intentionally giving the virus to an animal and then seeing if the vaccine prevents infection.